1. Home
  2. INAB vs FLGC Comparison

INAB vs FLGC Comparison

Compare INAB & FLGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INAB
  • FLGC
  • Stock Information
  • Founded
  • INAB 2016
  • FLGC 2019
  • Country
  • INAB United States
  • FLGC United States
  • Employees
  • INAB N/A
  • FLGC N/A
  • Industry
  • INAB Biotechnology: Pharmaceutical Preparations
  • FLGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • INAB Health Care
  • FLGC Health Care
  • Exchange
  • INAB Nasdaq
  • FLGC Nasdaq
  • Market Cap
  • INAB 18.8M
  • FLGC 17.3M
  • IPO Year
  • INAB 2021
  • FLGC 2021
  • Fundamental
  • Price
  • INAB $0.27
  • FLGC $0.87
  • Analyst Decision
  • INAB Strong Buy
  • FLGC Strong Buy
  • Analyst Count
  • INAB 3
  • FLGC 4
  • Target Price
  • INAB $5.57
  • FLGC $5.67
  • AVG Volume (30 Days)
  • INAB 14.2M
  • FLGC 276.0K
  • Earning Date
  • INAB 03-13-2025
  • FLGC 03-27-2025
  • Dividend Yield
  • INAB N/A
  • FLGC N/A
  • EPS Growth
  • INAB N/A
  • FLGC N/A
  • EPS
  • INAB N/A
  • FLGC N/A
  • Revenue
  • INAB N/A
  • FLGC $64,154,000.00
  • Revenue This Year
  • INAB N/A
  • FLGC N/A
  • Revenue Next Year
  • INAB N/A
  • FLGC $8.94
  • P/E Ratio
  • INAB N/A
  • FLGC N/A
  • Revenue Growth
  • INAB N/A
  • FLGC N/A
  • 52 Week Low
  • INAB $0.22
  • FLGC $0.72
  • 52 Week High
  • INAB $1.74
  • FLGC $2.93
  • Technical
  • Relative Strength Index (RSI)
  • INAB 47.53
  • FLGC 45.99
  • Support Level
  • INAB $0.25
  • FLGC $0.80
  • Resistance Level
  • INAB $0.30
  • FLGC $0.99
  • Average True Range (ATR)
  • INAB 0.04
  • FLGC 0.09
  • MACD
  • INAB 0.00
  • FLGC 0.02
  • Stochastic Oscillator
  • INAB 19.95
  • FLGC 39.16

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

About FLGC Flora Growth Corp.

Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are; the commercial and wholesale segment (FGH and Cosechemos subsidiaries), the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries), and the pharmaceuticals segment (Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). Geographically, the company generates revenue from United States, Germany, and the United Kingdom. It derives a majority of its revenue from the United States.

Share on Social Networks: